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Introduction
The E1-deleted replication-incompetent adenovirus vectors have extensively been used to transfer therapeutic genes into a variety of target cells in vivo. [1] [2] [3] [4] [5] However, recent studies have demonstrated that the replication defect in E1-deleted adenoviruses could be overcome in cultured cells at high multiplicities of infection (MOI) 6, 7 and that the early and late viral gene products can be expressed independently of E1a function following adenovirus-mediated gene transfer in vivo. [8] [9] [10] The expressed viral genes may elicit a host immune response in the transduced cells and lead to toxicity, 11, 12 limit the duration of transgene expression, [13] [14] [15] [16] and consequently hinder the application of these vectors for human gene therapy. To overcome these drawbacks, further modifications have been targeted to the E4 and E2 regions of adenovirus, which are critical for viral DNA synthesis and late gene production, to diminish the residual DNA replication of viral vectors and reduce their potential for viral gene expression. 3, 9, 17, 18 The E4 region is located at the right end of the viral genome and encodes a variety of genes and gene products that are essential for viral DNA replication, gene expression and viral particle assembly. 19, 20 E4 plays important roles in modulating the splicing of mRNAs encoding most of the late viral structure proteins through the function of the E4orf3 and E4orf6 proteins; 21, 22 in regulating the export of viral and cellular mRNAs by interaction between E4orf6 and E1B 55-kD protein; 23 and in mediating the function of viral (E1A) and cellular transcription factors by association of E4orf6 protein with endogenous phosphatase 2A. 24, 25 It has also recently been demonstrated that the E4orf6 protein disrupts binding of the p53 tumor suppressor gene to transcription factors, inhibiting p53-dependent transactivation and apoptosis. 26 Modification of the E4 region and removal of viral products that are assumed to have the negative effect on gene therapy are highly desirable. There have been promising attempts to modify the E4 region by either deleting the entire E4 or introducing alterations within individual E4 coding regions so as to minimize immunogenicity, eliminate the toxicity of adenoviral vectors and improve transgene persistence in vivo. 3, 17, 18, [27] [28] [29] [30] In this study, we developed a recombinant adenovirus with deleted E1 and E3 regions and an inactivated E4 to minimize expression of viral proteins. We used this vector to express a human tumor suppressor gene p53. We analyzed the effects of the E1 and E3 deletions and the E4 inactivation on viral gene replicaion and expression and on vector-mediated p53 gene expression and its function in human cancer cell lines. We also studied the toxicity and immunogenicity of this vector and the expression of p53 gene delivered by it in vivo in immunocompetent C3H and C57BL/6 mice.
Results

Diminished viral gene replication and expression in vitro
The potential for diminishing viral gene replication and expression by E4 promoter replacement was evaluated in human lung cancer cell lines H1299 and A549. Adenoviral replication was analyzed in adenovirus-transduced H1299 cells by Southern blot using the E4orf6 DNA (910 bp) fragment as a probe (Figure 1a) . At MOI 10, the total viral DNA in cells transduced by all the vectors remained unchanged from day 1 to day 7 after infection. At MOI 80, the total viral DNA in cells infected by BG and WT increased significantly from day 1 to day 7 after infection, however, the viral DNA production was dramatically retarded (Figure 1a ) and 20-to 25-fold lower in the G4-infected cells than in BG-and WT-infected cells at the same MOI (Figure 1b) .
Western blot analysis using a mouse anti-adenoviral hexon monoclonal antibody was carried out to investigate the effect of inactivated E4 on expression of the viral late gene (Figure 2a) . A consistent level of hexon protein was observed in both BG-and WT-infected H1299 cells (at MOI 10) and A549 cells (at MOI 50) on day 1 and day 7 after infection, but no hexon protein was detected in G4-infected cells. These results demonstrated that inactivation of the E4 promoter diminished viral replication and viral late gene expression in these human carcinoma cells.
Expression of p53 gene in vitro and its effects on tumor cell growth and apoptosis Western blot analysis using a mouse anti-human p53 monoclonal antibody was carried out to analyze vectormediated expression of the p53 gene in human carcinoma cell lines (Figure 2b) . The same high level of p53 protein was observed in both G4-and WT-transduced H1299 cells at MOI 10 throughout the time course of transduction (from day 1 to day 3), demonstrating that the E4 inactivation did not affect the efficiency of transgene expression in vitro.
To test the ability of recombinant adenoviruses carrying the human p53 gene for inhibition of cancer cell growth, different doses of virus were used to transduce H1299 cells (intrinsically deleted p53) and A549 cells (homozygous wild-type p53) (Figure 3a ). Cell growth rates were determined by MTT staining assay. At days 1, 2, 3, 4 and 7 after transduction, both WT and G4 constructs had inhibited H1299 cell growth dramatically at MOI 10 when compared with PBS and BG-transduced controls. The pattern and extent of growth inhibition by WT and G4 viruses were similar, indicating their similar levels of p53 gene expression. In addition, both WT and G4 constructs inhibited A549 cell growth at MOI 80 throughout the time course of transduction.
Since p53 gene-mediated cell growth inhibition is realized mainly through induction of apoptosis, apoptosis of virus-infected H1299 cells was determined by TUNEL staining and FACS (Figure 3b ). G4-infected and WT- infected H1299 cells demonstrated a similar level of apoptosis, indicating a similar mechanism of transgene function in both constructs.
Diminished viral protein expression in vivo
To study the effect of E4 inactivation on expression of viral proteins in vivo, we analyzed the expression of viral hexon protein in vector-injected mouse livers by in situ immunohistochemistry staining using mouse anti-adenoviral hexon monoclonal antibody (Figure 4) . Expression of viral hexon protein was observed in both BG-injected ( Figure 4c ) and WT-injected (Figure 4d ) mice after 3, 7 and 14 days, but was only visible at background levels in G4-treated mice at the same time-points (Figure 4b ). These observations indicate that the inactivation of the E4 promoter efficiently diminished late viral protein expression in vivo.
Reduced toxicity in mouse liver by E4 promoter inactivation To determine whether a vector with extensive deletion in its E1-E3 regions and inactivation of its E4 promoter would reduce toxicity in vivo, we used both C3H and C57BL/6 mice to study the liver toxicity induced by tailvein injection of EW and EG adenoviral constructs. PBS was used as a control. Vector-induced liver toxicity or damage was evaluated by analyzing the activities of the serum transaminases SGOT (Figure 5a 
Attenuated CTL response by E4 inactivation
The response of MHC class I-restricted CTL to adenoviral vectors and heterologous transgenes has been shown to play an important role in limiting the duration of transgene expression and inducing tissue toxicity. 12 We predicted that adenovirus vector with diminished viral gene expression would reduce cellular immunity. To evaluate these concepts, response of CTL to viral proteins and transgenes was analyzed in C57BL/6 mice injected with various recombinant adenovirus constructs ( Figure 7 ). Following i.v. administration of the vectors, spleen cells were harvested 2 weeks later, restimulated in vitro with E1-deleted type 5 adenovirus dl312 for 5-6 days, and then evaluated for CTL activity by analyzing LDH release from vector-infected syngeneic targets. CTL activity was noted in lymphocytes from C57BL/6 mice, the total CTL activities were two-to three-fold higher in animals treated with EW vector than in those treated with EG vector, suggesting that the diminished viral gene expression reduced vector-directed cellular immunity in these animals.
Discussion
We previously demonstrated that, at a high MOI of 100, E4 transcription was dramatically inhibited by E4 promoter replacement with GAL4/TATA in H1299 cells. 7 In this study, we further analyzed the effects of the E1-E3 deletion and E4 inactivation on viral gene replication and expression in vitro. At a high MOI of 80, the production of the viral DNA was dramatically retarded (20-to 25-fold lower) in cells infected with the E4-inactivated p53 expressing G4 vector, compared with those infected with the BG or WT vector. Thus, these results indicate that the replacement of the E4 promoter with the synthetic GAL4/TATA promoter efficiently inactivates E4 and diminishes the viral gene replication in non-E1 complementary cells. The viral replication we observed in H1299 cells was not due to the contamination with wildtype E1 in our constructs, as indicated by PCR analysis for replication-competent adenoviruses (RCA) (data not shown). Our results are consistent with other researchers' observations that the replication incompetence of E1-deleted adenovirus could be overcome by adenoviral infection at a high MOI in non-E1-transformed cells. 6, 18, 31 Synthesis of the late viral hexon was dramatically reduced by E4 inactivation in both G4-transfected H1299 and A549 cells at MOI 10 and MOI 50, respectively, compared with those in BG-and WT-infected cells. The reduction in accumulation of the late viral protein hexon correlated with reduction in virus production. These results suggest that diminished virus DNA replication and viral late-protein production can be similarly achieved by E4 transcriptional inactivation as by E4 deletion.
An efficient recombinant adenovirus vector system for gene therapy requires a stable, high level of expression of transgenes of interest both in cell culture and in vivo. Such systems can be developed by modifying cis sequences of the adenovirus vector backbone and the transcription unit of the transgene. The level of transcription, stability or translation of transgene mRNA depends on interaction between the cis elements in the recombi- nant vector and the trans activators in the cell hosts. Host immune responses to the early and late viral genes expressed by the E1-deleted first-generation vectors lead to toxicity and short-lived transgene expression in vivo. 1, 2, 5 The adenoviral E4orf6 protein has been shown to interact with the cellular p53 protein by binding to the C-terminal regulatory domain and to block p53-mediated transcriptional activation and apoptosis. 26 On the other hand, it has also been demonstrated that the persistence of expression depends on both the promoter used to control expression and the context of the E4 region. 17, 27 For example, a wild type of E4 region appears to be required for the persistence of CMV promoter-driven transgene expression in immunocompetent murine tissues. 17 We evaluated the effect of E4 inactivation by promoter replacement on CMV-directed p53 gene expression in vitro and in vivo to explore the potential of our G4 construct as an agent for cancer therapy. Western blot analysis of p53 expression in adenovirus-infected human lung carcinoma H1299 cells showed a similar high level expression of p53 in both WT-and G4-transfected cells. The growth of H1299 cells (in which p53 is deleted) was dramatically inhibited upon infection by both WT and G4 vectors at MOI 10, while inhibition of A549 cells (which carry wild-type p53) by both vectors was moderate at MOI 80. Furthermore, we demonstrated that both G4 and WT induced similar levels of apoptosis in transduced H1299 and A549 cells. Inhibition of growth and induction of apoptosis by overexpression of p53 in other types of tumors or tumor cells bearing wild-type p53 have also been reported by other researchers. 32, 33 These results indicate that the recombinant adenoviruses efficiently mediate CMV-driven p53 gene expression in vitro and that the level of p53 expression and its function are not affected by inactivation of E4.
We have reasoned that adenovirus vectors with an inactivated E4 would further diminish viral replication and might lead to prolonged transgene expression in vivo. Indeed, we report here that production of the late viral hexon protein was dramatically reduced in livers of both immunocompetent C3H and C57BL/6 mice treated with the E4-modified vectors. The hexon protein expression in G4-treated mice was only visible at background levels at the same time-points, suggesting that late gene expression is repressed in vivo when E4 is inactivated. These results are consistent with observations of in vitro
Figure 6 Immunohistochemical analysis of p53 gene expression in adenovirus-injected C57BL/6 mouse livers. Sections of formalin-fixed and paraffinembedded mouse liver tissue were analyzed by immunohistochemical staining with an FITC-conjugated mouse anti-human p53 monoclonal antibody and with 0.025% Evans Blue as counterstain. Immunocomplexes were examined under a fluorescence microscope with a dual light (red and green) filter. (a) Mock control (PBS); (b) negative control (at 3 days after injection with BG); (c) non-specific control (WT-treated liver section at 3 days after injection stained with an FITC-conjugated mouse anti-human integrin ␣ monoclonal antibody). (d-g) WT-injected mice; (h-k) G4-injected mice.
studies. 7 Moreover, we demonstrated p53 gene expression was prolonged in livers of C57BL/6 mice treated with E4-modified G4 vector versus WT. These results suggest that the inactivation of E4 by promoter replacement promote the persistence of p53 gene expression in vivo. Dedieu et al 18 have recently demonstrated that an E1-E4 doubly defective adenovirus promoted the persistence of the viral chromosome for at least 3 months in livers of C57BL/6 mice. However, the longterm persistence of the viral DNA in the liver was not associated with sustained expression of the transgene. Brough et al 34 have recently shown that persistence of transgene expression from adenovirus vectors is E4-dependent and that E4 gene products might be a potent cellular or viral modulators for activation of the adenoviral transgene expression cassettes. Meanwhile, Wilson's group 3 reported that a E1-E4 doubly defective adenovirus was capable of promoting CMV promoter-driven
Figure 7 CTL responses to recombinant adenoviruses in mice after i.v. inoculations. CTL responses in C57BL/6 mice with syngeneic CL4/SV40 cells as target. Error bars represent the standard errors. Statistically, differences between each treatment group are significant (Student's t test, P = 0.0065 between PBS and EW, 0.0167 between PBS and EG, and 0.0115 between EG and EW, respectively).
␤-galactosidase expression for at least 2 months in hepatocytes from ROSA-26 mice with mixed C57BL/6-129 genetic background. Armentano et al 17 has recently reported that CMV-driven transgene expression in murine lung persisted only in a vector with a wild-type E4 region, but not in vectors with E4orf6 or a completely deleted E4. These studies suggest that the inactivation of E4 (especially E4orf6) and the presence of the cis and trans elements in the E4 and viral backbone are required for the persistence of promoter-dependent transgene expression in vivo. In addition, our results suggest that the persistence of CMV-driven p53 gene expression mediated by the E4-inactivated adenovirus G4 seem to benefit from both the inactivation of E4 by promoter replacement and the presence of the regulatory elements in E4.
We expected that an adenovirus vector with the deleted E1 and E3, and an inactivated E4 would express lower levels of viral proteins, and thus reduce toxicity caused by the antigen-and nonantigen-specific immune responses. Decreased activities of SGOT and SGPT were observed in both C3H and C57BL/6 mice treated with E4-inactivated vector, compared with unmodified vector, indicating reduced toxicity to hepatocytes. The serum transaminases are useful indicators of hepatocellular necrosis in drug-induced toxicity studies in rodents. SGOT activity in particular has been proven to be very sensitive because of its high content in rodent liver tissue, which often results in a better correlation with histopathology. 35 Gao et al 3 have used serum transaminase ALP level as a biochemical measure of liver toxicity and shown that the reduced ALP level is reduced in C3H and C57BL/6 mice injected with E1-E4 doubly defective adenovirus. However, the intensity and peak activity of ALP they observed were different from those of SGOT and SGPT we observed in both C3H and C57BL/6 mice, which could partially be explained by the observation that the serum ALP is commonly considered an indicator of biliary tract disorders that is neither organ-specific nor sensitive for rodents. 3, 35 It has been reported that host pathological responses to recombinant adenovirus are strikingly strain-specific and that they also depend on both the structure of the vector backbone and the transgene it encodes. 3, 18, 36 The reduced toxicity seen was probably due to the diminished viral protein production of the E4-inactivated vector. This is supported by the observation that liver enzyme elevation was minimal following injection of the E4-modified empty vector (EG) compared with the empty wild-type vector (EW).
Substantial efforts have been made to develop less immunogenic vectors by introducing additional modifications to E2, E4 and all viral coding genes. 3, 9, 10, 13, 18, 28, 37 These efforts are based on the hypothesis that the diminished expression of late viral proteins will lead to reduced immunogenicity, thus preventing the destruction of the transduced cells and prolonging transgene expression. In this study, we analyzed the CTL responses to the viral protein and transgenes in virus-injected C57BL/6 mice to evaluate the effect of E4 inactivation on vector-induced immunogenicity. We observed that the total CTL activities were two-to three-fold higher in animals treated with EW than in those treated with E4 modified EG vector, suggesting that the diminished viral gene expression contributed greatly to the reduced cellular immunity in these animals and probably to reduced vector-derived inflammation. The findings from our present study suggest that it would be possible to prevent the threshold needed for CTL activation by minimizing the expression of viral antigens via modification of the adenovirus genome. However, CTL responses may differ between mice and humans, and are likely to vary within diverse human populations. Moreover, the requirement for CTL activation and expansion depends on immunogens, antigen presenting cells and target cells, factors that could complicate the design of less immunogenic vectors for gene therapy.
As a delivery system for adenovirus-mediated gene therapy, the G4 vector we have described here offers several advantages over other adenoviral vectors. First, it is potentially safer because of its diminished viral gene replication, reduced toxicity and attenuated immunogenicity. Second, it can prolong expression of p53 gene in vivo. Third, it diminishes RCA contamination of E4 by avoiding the need for E4-complementary virus-producing cells. Fourth, it allows the easy production of virus of high titers, 7 which is somehow hampered by adenovirus constructs containing defective E2 38 or E4. 17 Finally, the inactivation of E4 in the G4 vector effectively silences expression of the E4orf6 protein which has been reported to inhibit the transactivation of p53 and its biological activities in vitro. 26 Together, these advantages suggest that the G4 vector will prove useful for gene delivery in vivo.
Materials and methods
Cell lines
The 293 cell line and the transformed 293/GV16 cell line expressing yeast GAL4/VP16 transactivating proteins 7 were used in the construction, amplification and titration of adenoviral vectors. Both cell lines were maintained in Dulbecco's modified Eagle medium (DMEM) containing 4.5 g/l of glucose with 10% FBS. H1299 cells were maintained in RPMI 1640 medium supplemented with 5% 400 FBS. A549 cells were maintained in F-12 nutrient mixture (HAM) with 10% FBS. The syngeneic 1422 cell line derived from a C3H/NeH tumor was kindly provided by Dr Amanthaswarmy at The University of Texas MD Anderson Cancer Center, Houston, TX, USA. The CL4/SV40 cell line derived from C57BL/6 mouse fibroblasts transformed by SV40 was obtained from American Type Culture Collection (Rockville, MD, USA). Both 1422 and CL4/SV40 cell lines were maintained in DMEM with 10% FBS. All cell lines were cultured at 37°C in a humidified atmosphere of 95% air and 5% CO 2 .
Production of recombinant adenoviruses
All recombinant adenovirus vectors used in this study were based on the adenovirus serotype 5, and they were constructed as described previously. 7 (1) Adv-cmv-hp53-GAL4 (G4), a recombinant virus contained E4 modification in which E4 promoter was replaced with a synthetic promoter sequence composed of a minimal TATA box and five consensus 17-mer yeast GAL4-binding site elements 7 and a CMV-human p53 expression cassette was inserted into the deleted E1 region. − vector contained E4 modification. All viral vectors were expanded in 293 or 293/VP16 cells 7 and then purified by CsCl gradient ultracentrifugation. Viral titers were determined by both optical density (OD) measurement and plaque assay. The p53 gene and GAL4/TATA sequences were confirmed by automatic DNA sequencing. Potential contamination of the viral preparation by the wild-type virus was monitored by PCR analysis.
Determination of cell growth rate Inhibition of cell growth by adenovirus infection was assayed by MTT staining (Sigma, St Louis, MO, USA). In brief, experimentally treated cells were harvested and 200 l of cell suspension was added to each well in 96-well plates. A one-tenth volume of MTT solution (5 mg MTT/ml PBS) was added to each well, and each plate was incubated for 2-4 h at 37°C until a purple precipitate was visible. The medium was then carefully removed, and precipitates were dissolved in 100 l DMSO. The number of viable cells was determined by measuring absorbency at 570 nm with background subtraction at 630-690 nm and calculated by comparing with known numbers of cells in the standards. Growth rate was plotted as the percentage of the PBS-treated control group.
Apoptosis analysis
Apoptosis was analyzed by FACS using the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) reaction with fluorescein (FITC)-labeled dUTP (Boehringer Mannheim Biochemicals, Germany). In brief, cells were seeded on 60-mm plates and infected with adenovirus constructs. PBS containing no viral constructs was used as a control. Cells were then harvested by centrifugation at 300 g for 10 min and washed twice with PBS. Harvested cells (1-2 × 10 7 ) were fixed in 1% formaldehyde for 15 min at 4°C and permeabilized in 100 l 0.1% Triton X-100 and 0.1% sodium citrate solution for 2 min on ice. Cells were then washed twice with PBS, resuspended in 50 l TUNEL reaction mixture (0.2 m potassium cacodylate, 25 mm Tris-HCl, pH 6.6, 2.5 mm cobalt chloride, 0.25 mg/ml BSA, 100 U/ml TdT and 10 m FITC-dUTP), and incubated for 60 min at 37°C in a humidified atmosphere in the dark. After incubation, cells were washed twice in PBS and resuspended in 250-500 l PBS. Apoptosis was analyzed by FACS for DNA fragmentation.
Western blot analysis Expression of late viral hexon protein and p53 in transfected cells was analyzed by Western blot analysis. Cells grown in 100-mm dishes (2-5 × 10 7 per dish) were treated with adenoviruses and PBS alone was used as a control. Cells were harvested, rinsed once with PBS and lysed with SDS-PAGE loading buffer. Total proteins were assayed by the BCA method (Pierce, Rockford, IL, USA). Proteins were separated by SDS-PAGE. Each lane was loaded with 20 g cell lysate protein and electrophoresed at 100 V for 1-2 h. Proteins were then transferred from gels to Hybond-ECL membranes (Amersham International, UK). Membranes were blocked in blocking solution (3% dry milk, 0.1% Tween 20 in PBS) for 1 h at room temperature. Membranes were then incubated with 1:500-1:1000 dilution of mouse anti-human p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and antiadenovirus hexon (Chemicon, Temecula, CA, USA) monoclonal antibodies. Immunocomplexes were detected using an ECL kit (Amersham) according to the manufacturer's instructions.
Southern blot analysis
Adenovirus replication in H1299 cells was analyzed by Southern blot analysis. Cells (5 × 10 7 cells) were seeded in 100-mm dishes and infected with adenoviruses at MOIs of 10 and 80 plaque forming units (p.f.u.) per cell. Cells were harvested 1, 3 and 7 days after viral inoculation. Cellular DNA was isolated using Trizol reagent (Life Technology, Hoston, TX, USA). Then, 20 g DNA was digested with BamHI and fragmented by electrophoresis on a 0.8% agarose gel. Separated DNA fragments were transferred to a nylon membrane (GeneScreen; NEN Research Products, Boston, MA, USA) and probed for the viral DNA with a 32 P-labeled E4orf6 DNA fragment (910 bp). Images were generated and analyzed using a Phosphoimage Analysis System (Molecular Dynamics, Sunnyvale, CA, USA).
Animal studies C57BL/6 mice and C3H/HeN were obtained from Charles River (Cambridge, MA, USA). All animals were maintained and all animal experiments were conducted under institutional guidelines established for the Animal Core Facility at the MD Anderson Cancer Center. Five mice were used for each treatment group. Each mouse (8 to 10 weeks old) was injected with 100 l of adenoviruses (10 10 p.f.u.) in PBS via the tail vein. Blood samples were collected from the tail at days 3, 7, 14 and 28 after injection, respectively, and assayed for SGOT and SGPT activities according to standard procedures. At designated time-points, animals were killed with CO 2 . Their livers were collected for pathological and immunohistochemical analysis and their spleens for cytotoxic T lymphocytes (CTL) assay.
Immunohistochemistry
The formalin-fixed and paraffin-embedded liver sections were deparaffinized in three changes of xylene solution for 10 min each, hydrated in gradually diluted ethanol (100-95-80-70%), and washed three times with PBS. For the frozen sections, liver tissues were frozen with OTC, cut into 4-m-thick sections, and fixed in cold acetone for 10 min and rinsed in three changes of PBS. Samples were then incubated in PBS with 10% normal serum for 20 min at room temperature and washed once with PBS. For adenoviral hexon staining, samples were incubated with FITC-conjugated mouse anti-hexon monoclonal antibody (0.1-2.0 g/ml in PBS-BSA) (Chemicon International) or FITC-conjugated mouse anti-human p53 monoclonal antibody (0.1-2.0 g/ml in PBS-BSA) (Santa Cruz Biotechnology) for 30 min at 37°C in the dark. A FITCconjugated mouse anti-human integrin ␣ monoclonal antibody (Chemicon International) was used as a nonspecific control. The mean percentage of p53-expressing cells in liver was estimated by counting three random fields at 40 times magnification under a fluorescent microscope. Apoptosis was detected by in situ immunohistochemical staining of frozen liver tissue sections using theTUNEL reaction and FITC-labeled dUTP (Boehringer Mannheim). Finally, sections were washed twice with PBS, mounted with fluorescence mounting medium (Vector Laboratories, Burlingame, CA, USA) and examined under a fluorescence microscope.
CTL assay
Mice were killed 2-3 weeks after i.v. injection of adenoviruses (10 10 p.f.u. per mouse). Single-cell suspensions of splenocytes were made and pooled from three mice in each treatment group. Lymphocytes were isolated on a Ficoll-Hypaque (Sigma) gradient, washed twice and then plated on to 24-well plates at 2 × 10 6 cells per well. Lymphocytes were restimulated in vitro for 5-6 days with purified E1-deleted type 5 adenovirus Dl312 virus at MOI 1. Syngeneic CL4/SV40 cells were used as target cells for C57BL/6-originated effectors. Target cells were infected with WT virus at MOI 80 for 24 h. Uninfected cells were used as control target cells. The CTL assay was performed by quantitatively measuring lactate dehydrogenase (LDH) release upon cell lysis using the CytoTox 96 Assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Results were calculated from the mean of quadruplicate samples and presented as the percent cytotoxicity for each effector:target cell ratio. The differences among treatments were statistically analyzed with t test and t distribution.
